The lead drug emerging from the biotech's Helicon platform is billed as a "first-and-only-in-class" direct TCF-blocking beta-catenin inhibitor, which FogPharma says has potential as a treatment ...

Overholtzer et al. also noticed that before internalization, cells establish E-cadherin–beta-catenin-mediated adherens junctions and the compaction of these junctions appears to directly mediate ...